Home Cart Sign in  
Chemical Structure| 4670-05-7 Chemical Structure| 4670-05-7

Structure of Theaflavin
CAS No.: 4670-05-7

Chemical Structure| 4670-05-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Theaflavin, a type of thearubigins, exhibits inhibition of xanthine oxidase enzyme and can scavenge various oxidation radicals with anti-oxidant and anti-tumor activities. It can be purified from the leaves of Camellia sinensis (L.) O. Kuntze.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Theaflavin

CAS No. :4670-05-7
Formula : C29H24O12
M.W : 564.49
SMILES Code : O=C1C(O)=CC([C@@H]2[C@H](O)CC3=C(O2)C=C(O)C=C3O)=CC4=C([C@@H]5[C@H](O)CC6=C(O5)C=C(O)C=C6O)C=C(O)C(O)=C41
MDL No. :MFCD03427500
InChI Key :IPMYMEWFZKHGAX-ZKSIBHASSA-N
Pubchem ID :135403798

Safety of Theaflavin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BMDMs 50, 100, 200 µM 1 hour Theaflavin dose-dependently inhibited NLRP3 inflammasome activation induced by ATP or nigericin, as evidenced by reduced release of caspase-1p10 and mature IL-1β. Acta Pharmacol Sin. 2023 Oct;44(10):2019-2036.
J774A.1 cells 50, 100, 200 µM 1 hour Theaflavin dose-dependently inhibited NLRP3 inflammasome activation induced by ATP or nigericin, as evidenced by reduced release of caspase-1p10 and mature IL-1β. Acta Pharmacol Sin. 2023 Oct;44(10):2019-2036.
3T3-L1 adipocytes 100 µM 10 days To evaluate the effects of theaflavin-3,3'-digallate on methylmercury-exposed 3T3-L1 adipocytes. Results showed that 100 µM TF-3 partially restored adipocyte morphology and adipokine secretion patterns. Int J Mol Sci. 2019 Jun 5;20(11):2755
3T3-L1 adipocytes 50 µM 10 days To evaluate the effects of theaflavin-3,3'-digallate on methylmercury-exposed 3T3-L1 adipocytes. Results showed that 50 µM TF-3 partially restored adipocyte morphology and adipokine secretion patterns. Int J Mol Sci. 2019 Jun 5;20(11):2755
3T3-L1 adipocytes 25 µM 10 days To evaluate the effects of theaflavin-3,3'-digallate on methylmercury-exposed 3T3-L1 adipocytes. Results showed that 25 µM TF-3 significantly restored adipocyte morphology and adipokine secretion patterns. Int J Mol Sci. 2019 Jun 5;20(11):2755
3T3-L1 adipocytes 12.5 µM 10 days To evaluate the effects of theaflavin-3,3'-digallate on methylmercury-exposed 3T3-L1 adipocytes. Results showed that 12.5 µM TF-3 partially restored adipocyte morphology and adipokine secretion patterns. Int J Mol Sci. 2019 Jun 5;20(11):2755
3T3-L1 adipocytes 6.25 µM 10 days To evaluate the effects of theaflavin-3,3'-digallate on methylmercury-exposed 3T3-L1 adipocytes. Results showed that 6.25 µM TF-3 significantly improved adipocyte morphology and adipokine secretion patterns. Int J Mol Sci. 2019 Jun 5;20(11):2755
3T3-L1 adipocytes 3.14 µM 10 days To evaluate the effects of theaflavin-3,3'-digallate on methylmercury-exposed 3T3-L1 adipocytes. Results showed that 3.14 µM TF-3 partially restored the morphological changes and adipokine secretion patterns induced by methylmercury. Int J Mol Sci. 2019 Jun 5;20(11):2755
HK-2 cells 20 and 50 μg/ml 2 hours pretreatment followed by 24 hours To evaluate the protective effect of theaflavin on COM-induced oxidative stress injury in renal tubular epithelial cells. Results showed that theaflavin significantly enhanced SOD activity, reduced LDH, MDA, and H2O2 levels, decreased intracellular ROS generation, and upregulated SIRT1 expression. Int J Biol Sci. 2021 Mar 2;17(4):1050-1060
Human subcutaneous fat cells (hSCF) 0.5 to 2 μg/mL (TF and TFDG) 21 days To assess the effects of theaflavin on adipocyte differentiation. Results showed that theaflavin (TF) increased intracellular lipid droplet formation at concentrations ranging from 0.5 to 2 μg/mL, while theaflavin-3,3'-digallate (TFDG) inhibited lipid droplet formation. Int J Mol Sci. 2019 Apr 25;20(8):2034
Human subcutaneous fat cells (hSCF) 1 to 5 μg/mL 24 and 72 hours To evaluate the effects of theaflavin on cell proliferation and viability. Results showed that theaflavin increased cell proliferation after 24 h, and no cytotoxicity was observed after 72 h, with a slight increase in cell viability in some cases. Int J Mol Sci. 2019 Apr 25;20(8):2034
A875 melanoma cells 240 µg/ml (464.7 µM) 24 hours To evaluate the effect of theaflavin on another melanoma cell line. Results showed that theaflavin significantly inhibited the viability of A875 cells. Front Pharmacol. 2020 Aug 31;11:1317
HFF-1 skin fibroblasts 240 µg/ml (464.7 µM) 24 hours To evaluate the effect of theaflavin on normal cells. Results showed that theaflavin had little effect on the viability of HFF-1 cells. Front Pharmacol. 2020 Aug 31;11:1317
Human umbilical vein endothelial cells (HUVECs) 0, 25, 50 µM 24 hours To evaluate the protective effect of Theaflavin on TBHP-induced oxidative stress. Results showed that Theaflavin alleviated apoptosis and cell dysfunction and activated the PI3K/AKT/Nrf2 signaling pathway. Front Bioeng Biotechnol. 2022 Mar 2;10:830574
A375 human melanoma cells 50-400 µg/ml (96.8-744.4 µM) 24, 48, 72 hours To evaluate the anti-proliferative and pro-apoptotic effects of theaflavin on melanoma cells. Results showed that theaflavin significantly inhibited the proliferation of A375 cells in a concentration-dependent manner, with IC50 values of 218.9 µg/ml (423.8 µM) at 24 hours and 84.9 µg/ml (164.4 µM) at 72 hours. Front Pharmacol. 2020 Aug 31;11:1317
Porcine nasopharyngeal epithelial cell Nptr 256 µg/mL (1/2 MIC) 30 minutes Evaluate the effect of theaflavin on the adhesion ability of Streptococcus suis SC19, results showed significantly reduced adhesion Int J Mol Sci. 2023 Apr 18;24(8):7442
Porcine nasopharyngeal epithelial cell Nptr 128 µg/mL (1/4 MIC) 30 minutes Evaluate the effect of theaflavin on the adhesion ability of Streptococcus suis SC19, results showed reduced adhesion Int J Mol Sci. 2023 Apr 18;24(8):7442
Porcine nasopharyngeal epithelial cell Nptr 512 µg/mL 30 minutes Evaluate the cytotoxicity of theaflavin on Nptr cells, results showed no cytotoxicity Int J Mol Sci. 2023 Apr 18;24(8):7442
Drosophila intestinal cells 1 mg/mL and 2.5 mg/mL Continuous feeding Theaflavins extend Drosophila lifespan and increase climbing ability iScience. 2021 Feb 6;24(3):102150

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Larval zebra fishes A375 xenograft model Dissolved in culture medium 0.22, 0.67, 2.0 mg/ml (0.4, 1.3, 3.9 µM) 24 hours To evaluate the inhibitory effect of theaflavin on melanoma growth in vivo. Results showed that theaflavin significantly inhibited A375 tumor growth in larval zebra fishes, with an inhibitory rate of 46.4% at 2.0 mg/ml (3.9 μM), outperforming cisplatin. Front Pharmacol. 2020 Aug 31;11:1317
Drosophila melanogaster W1118 Drosophila Dietary supplementation 1 mg/mL and 2.5 mg/mL Continuous feeding Theaflavins extend Drosophila lifespan and increase climbing ability iScience. 2021 Feb 6;24(3):102150
Male albino Wistar rats High fat diet and streptozotocin-induced diabetic rat model Oral 100 mg/kg b.w/day Once daily for 30 days To evaluate the effect of theaflavin on the activities of key enzymes of carbohydrate metabolism in high fat diet and streptozotocin-induced diabetic rats. The results showed that theaflavin significantly ameliorated plasma glucose, insulin levels, HOMA-IR index, HbA1c, and glycogen content in liver and muscle. Additionally, theaflavin reduced lipid peroxidation markers (TBARS and hydroperoxides) and enhanced the activities of antioxidant enzymes. Redox Rep. 2019 Dec;24(1):41-50
Sprague-Dawley rats Full-thickness skin wound model Oral 20 mg/kg Once daily until the end of the experiment To evaluate the promoting effect of Theaflavin on wound healing. Results showed that Theaflavin enhanced vascularization in regenerated tissues and accelerated wound healing. Front Bioeng Biotechnol. 2022 Mar 2;10:830574
C57BL/6J male mice CaOx nephrocalcinosis mouse model Gavage 20, 50, and 100 mg/kg Once daily for 14 days To evaluate the protective effect of theaflavin on CaOx-induced kidney oxidative stress injury and crystal deposition. Results showed that theaflavin significantly reduced crystal deposition, alleviated tissue damage and apoptosis, and improved oxidative stress status. Int J Biol Sci. 2021 Mar 2;17(4):1050-1060
C57BL/6J mice MSU-induced peritonitis model Oral 250 mg/kg Once daily for three consecutive days Theaflavin significantly attenuated MSU-induced peritonitis in mice, as shown by reduced levels of IL-1β and IL-6 in peritoneal lavage fluids and decreased neutrophil infiltration. Acta Pharmacol Sin. 2023 Oct;44(10):2019-2036.
Sprague-Dawley rats Middle cerebral artery occlusion (MCAO) model Intravenous injection 5, 10, and 20 mg/kg Single administration, lasting 24 hours Theaflavin significantly protected neurons from cerebral ischemia-reperfusion injury by limiting leukocyte infiltration and expression of ICAM-1, and suppressing upregulation of inflammatory-related prooxidative enzymes (iNOS and COX-2) in ischemic brain via, at least in part, reducing the phosphorylation of STAT-1. Mediators Inflamm. 2006;2006(5):30490
Kun-Ming mice Streptococcus suis SC19 infection model Intragastrically 50 mg/kg Single administration, observed for 7 days post-infection Evaluate the protective effect of theaflavin on infected mice, results showed survival rate increased to 40% and clinical symptoms were alleviated Int J Mol Sci. 2023 Apr 18;24(8):7442

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03194620 Healthy Not Applicable Completed - United States, California ... More >> UC Davis Davis, California, United States, 95616 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.77mL

0.35mL

0.18mL

8.86mL

1.77mL

0.89mL

17.72mL

3.54mL

1.77mL

References

 

Historical Records

Categories